- Home
- SMBK vs IMNM Comparison
SMBK vs IMNM Comparison
Compare SMBK & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMBK
- IMNM
- Stock Information
- Founded
- SMBK N/A
- IMNM 2006
- Country
- SMBK United States
- IMNM United States
- Employees
- SMBK N/A
- IMNM N/A
- Industry
- SMBK Major Banks
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- SMBK Finance
- IMNM Health Care
- Exchange
- SMBK Nasdaq
- IMNM Nasdaq
- Market Cap
- SMBK 538.6M
- IMNM 542.6M
- IPO Year
- SMBK N/A
- IMNM 2020
- Fundamental
- Price
- SMBK $28.88
- IMNM $7.91
- Analyst Decision
- SMBK Buy
- IMNM Strong Buy
- Analyst Count
- SMBK 6
- IMNM 6
- Target Price
- SMBK $30.50
- IMNM $26.00
- AVG Volume (30 Days)
- SMBK 60.0K
- IMNM 1.7M
- Earning Date
- SMBK 04-21-2025
- IMNM 05-13-2025
- Dividend Yield
- SMBK 1.11%
- IMNM N/A
- EPS Growth
- SMBK 26.63
- IMNM N/A
- EPS
- SMBK 2.14
- IMNM N/A
- Revenue
- SMBK $166,349,000.00
- IMNM $9,041,000.00
- Revenue This Year
- SMBK $19.20
- IMNM N/A
- Revenue Next Year
- SMBK $9.76
- IMNM $1,259.12
- P/E Ratio
- SMBK $13.45
- IMNM N/A
- Revenue Growth
- SMBK 11.36
- IMNM N/A
- 52 Week Low
- SMBK $19.01
- IMNM $5.15
- 52 Week High
- SMBK $37.72
- IMNM $19.07
- Technical
- Relative Strength Index (RSI)
- SMBK 43.06
- IMNM 55.28
- Support Level
- SMBK $26.84
- IMNM $6.96
- Resistance Level
- SMBK $28.77
- IMNM $7.56
- Average True Range (ATR)
- SMBK 1.22
- IMNM 0.69
- MACD
- SMBK 0.07
- IMNM 0.26
- Stochastic Oscillator
- SMBK 51.09
- IMNM 98.22
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.